His treatment with REGN-COV2 monoclonal antibodies to coronavirus was administered to President Donald Trump last week after he was diagnosed with Covid-19. He has since described it as a treatment, although there is no scientific evidence to that effect.
Regeneron announced on Wednesday that “if it receives such an authorization, the government has promised to make the doses available to the Americans, free of charge, and will assume their distribution.”
The treatment is currently available for 50,000 patients, according to Regeneron, which expects to deliver doses for 300,000 patients in the coming months.
REGN-COV2 is a combination of two monoclonal antibodies and was “created specifically to block the infectivity” of the virus that causes Covid-19.
Trump received 8 grams of the antibody cocktail in the early stages of his infection, even though it is not authorized by the FDA.
Regeneron said studies have shown that REGN-VOC2 has reduced the virus’s viral load and associated damage to primate lungs. The company recently partnered with Roche to increase the supply of REGN-VOC2 globally if treatment is approved.
“If REGNCOV2 proves to be safe and effective in clinical trials and receives regulatory approval, Regeneron will produce and distribute it in the United States (beyond the offer to the US government), and Roche will develop, produce and distribute it in the United States. outside the United States, “Regeneron said.